Sign in

    Dylan Shindler

    Biotechnology Equity Research Associate at Wedbush Securities

    Dylan Shindler is a Biotechnology Equity Research Associate at Wedbush Securities, specializing in equity analysis of biotech companies since May 2024. He has been involved in comprehensive company analysis, maintaining financial models, and preparing research reports, with prior experience as an Equity Research Analyst Intern at Wedbush in 2023 and additional background at Payne and Dolan, Inc. and Pillar Booth. Shindler holds a Bachelor’s degree in Civil Engineering from the University of Wisconsin-Madison, earned in 2023, and has passed the Series 16 exam. His research focus includes coverage of dynamic biotechnology firms, backed by a strong foundational expertise in financial and technical analysis within the sector.

    Dylan Shindler's questions to Xenon Pharmaceuticals (XENE) leadership

    Dylan Shindler's questions to Xenon Pharmaceuticals (XENE) leadership • Q1 2025

    Question

    Dylan Shindler, on for Laura Chico, asked about the expected enrollment timeline for the X-TOLE3 study relative to X-TOLE2 to better understand the separation between the two data readouts.

    Answer

    President and CEO Ian Mortimer explained that X-TOLE2 was prioritized and initiated first, meaning X-TOLE3 is on a later timeline. While not providing specific guidance for X-TOLE3's completion, he confirmed its readout will be later than X-TOLE2's and that more detailed guidance would be provided later in the year.

    Ask Fintool Equity Research AI